


Serial No. 10/500,517

Applicants respectfully advise that this application does not contain a nucleotide and/or amino acid sequence disclosure; therefore, no further documentation should be required.

Respectfully submitted,



Mark A. Winter
Agent for Applicants
Registration No. 53,782
Phone: 317-276-5362

Eli Lilly and Company
Patent Division/MAW
P.O. Box 6288
Indianapolis, Indiana 46206-6288



UNITED STATES PATENT AND TRADEMARK OFFICE

Rec'd PCT/PTO 27 SEP 2004

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO	FIRST NAMED APPLICANT	ATTY DOCKET NO.
10/500,517	Peter Charles Astles	X-14688

25885
 ELI LILLY AND COMPANY
 PATENT DIVISION
 P.O. BOX 6288
 INDIANAPOLIS, IN 46206-6288

RECEIVED

SEP 21 2004

ELI LILLY & COMPANY, PATENT DEPT.

Date Mailed: 09/16/2004

INTERNATIONAL APPLICATION NO.	
PCT/US02/21297	
1A FILING DATE	PRIORITY DATE
07/29/2002	01/17/2002

CONFIRMATION NO. 8378
 371 FORMALITIES LETTER



OC000000013800963

Due 11-16-04

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c) and PCT Rule 5.2(a).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631